The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Phage-Derived Peptidoglycan Degrading Enzymes: Challenges and Future Prospects for In Vivo Therapy
Open accessAbstract
Peptidoglycan degrading enzymes are of increasing interest as antibacterial agents, especially against multi-drug resistant pathogens. Herein we present a review about the biological features of virion-associated lysins and endolysins, phage-derived enzymes that have naturally evolved to compromise the bacterial peptidoglycan from without and from within, respectively. These natural features may determine the adaptability of the enzymes to kill bacteria in different environments. Endolysins are by far the most studied group of peptidoglycan-degrading enzymes, with several studies showing that they can exhibit potent antibacterial activity under specific conditions. However, the lytic activity of most endolysins seems to be significantly reduced when tested against actively growing bacteria, something that may be related to fact that these enzymes are naturally designed to degrade the peptidoglycan from within dead cells. This may negatively impact the efficacy of the endolysin in treating some infections in vivo. Here, we present a critical view of the methods commonly used to evaluate in vitro and in vivo the antibacterial performance of PG-degrading enzymes, focusing on the major hurdles concerning in vitro-to-in vivo translation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Antibiotic resistance-the need for global solutions
Laxminarayan, R., Duse, A., Wattal, C., Zaidi, A. K. M., Wertheim, H. F. L., Sumpradit, N., Vlieghe, E., Hara, G. L., Gould, I. M., Goossens, H., et al. (2013) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(13)70318-9 · Cited by 4,439
Peptidoglycan types of bacterial cell walls and their taxonomic implications
Schleifer, K. H., & Kandler, O. (1972) · Bacteriological Reviews · doi:10.1128/mmbr.36.4.407-477.1972 · Cited by 4,223
Multistate point-prevalence survey of health care-associated infections
Magill, S. S., Edwards, J. R., Bamberg, W., Beldavs, Z. G., Dumyati, G., Kainer, M. A., Lynfield, R., Maloney, M., McAllister-Hollod, L., Nadle, J., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1306801 · Cited by 3,931
Bacteriophage virion-associated peptidoglycan hydrolases: potential new enzybiotics
Rodríguez-Rubio, L., Martínez, B., Donovan, D. M., Rodríguez, A., & García, P. (2013) · Critical Reviews in Microbiology · doi:10.3109/1040841x.2012.723675 · Cited by 173
Cited by
The global preclinical antibacterial pipeline
Theuretzbacher, U., Outterson, K., Engel, A., & Karlén, A. (2020) · Nature Reviews Microbiology · doi:10.1038/s41579-019-0288-0 · Cited by 738
Bacteriophage therapy as an alternative treatment for human infections. A comprehensive review
Kakasis, A., & Panitsa, G. (2019) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2018.09.004 · Cited by 261
Metadata
- Authors
- Oliveira, H., São-José, C., & Azeredo, J.
- Venue
- Viruses
- Publisher
- MDPI AG
- Published
- 2018-05-29
- Volume
- 10
- Issue
- 6
- Pages
- 292
- ISSN
- 1999-4915 (ISSN-L)
- OpenAlex
- W2807288737
- Cited by
- 170
- References
- 4
- FWCI
- 9.60
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Phage-Derived Peptidoglycan Degrading Enzymes: Challenges and Future Prospects for In Vivo Therapy. https://app.cochat.ai/papers/10.3390/v10060292
- The paper
- Oliveira, H., São-José, C., & Azeredo, J. (2018). Phage-Derived Peptidoglycan Degrading Enzymes: Challenges and Future Prospects for In Vivo Therapy. Viruses. https://doi.org/10.3390/v10060292
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.